Manifestationsspacer
     
  deutsch | français
Assemblées annuellesCongrès annuel 2010Congrès annuel 2009Congrès annuel 2008Congrès annuel 2011
CalendrierPrésentations
Nouveautés
Contact
Chercher
Sitemap
Imprimer
Besucher seit 04.08.09: 5393
Statistique Sep 2010
Consultations2668
Quantité de données71.29 MB
Cette statistique est actualisée
quotidiennement

 

Webmaster

Dernière mise à jour:
05.07.2010, 10:44

Assemblée annuelle 2009

 

Date:
13 –15 mai 2009
Lieu: Bâle – Congress Center

 

Inscription, informations et détails: sous www.congress-info.ch/sgim2009

 

 

Aperçu du programme

 

 

Jeudi, 14 mai 2009
 
12h30 – 13h30

Assemblée générale SSH     

 

 

 

Symposium SSH, 1ère partie

 

Myeloproliferative Neoplasms in 2009
Chairpersons: André Tichelli, Basel / Andreas Tobler, Bern

14h00–14h30 The molecular pathogenesis of myeloproliferative disorders
Radek Skoda, Basel
14h30–15h00

20 years of Interferon therapy for Ph-negative myeloproliferative disorders: from hematological to molecular response
Jean-Jacques Kiladjian, Bobigny FR

 

 

15h00 – 15h45
Presidential Symposium SGH
 

Discours des lauréats

 

Prix de l’hématologie clinique
Abstract No 1 SSH
Jakob Passweg, Genève


Prix de l’hématologie expérimentale
Abstract No 2 SSH
Nicolas Bonadies, Cambridge GB


Remise du prix hémostase Roche et discours du lauréat

 

 

 

Symposium SSH, 2ème partie

 

Iron and Anemia
Chairpersons: Jean-Philippe Grob, Lausanne / Ulrich Buser, Basel

16h15–16h45

Iron deficiency anemia in the light of recent findings in iron metabolism

Photis Beris, Genève

16h45–17h15

Anemia of chronic disease

Sigismond Lasocki, Paris FR

17h15–17h45

Anemia in the elderly

Elizabeth A. Price, Palo Alto US

 

 

dès 20h00
Soirée sociale SSH

 

 

 

 

Vendredi, 15 mai 2009
 
  Communications libres SSH session 1
8h45 – 10h45

Experimental Hematology

Chairpersons: Olivier Spertini, Lausanne / Martin Fey, Bern

FM40

Donor T Cell Production of IL-21 Accelerates Graft-Versus-Host Disease Lethality

Bucher C., Vogtenhuber C., Jasperson L., Goren E., Panoskaltsis-Mortari A., Sivakumar P., Blazar B. (Minneapolis, Seattle)

FM41

Large-scale clinical grade expansion of alloreactive haploidentical natural killer cells for multiple infusions to leukemia patients

Siegler U., Meyer-Monard S., Jörger S., Stern M., Tichelli A., Gratwohl A., Wodnar-Filipowicz A. (Basel)

FM42

Involvement of microRNAs in post-transcriptional regulation of NKG2D ligand expression in human tumor cell lines

Himmelreich H., Mathys A., Wodnar-Filipowicz A., Kalberer C. (Basel)

FM43

HUMAN EMBRYONIC STEM CELLS DIFFERENTIATED IN ABSENCE OF XENOGENIC COMPOUNDS GENERATE CD34+ AND CD34- HEMATOPOIETIC CELLS WITH DISTINCT PROGENITOR CHARACTERISTICS

Chicha L., Jaconi M., Passweg J., Kindler V. ( Geneva)

FM44

Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as essential regulator of SDF1α/CXCR4-mediated homing and migration

Schwaller J., Brault L., Grundler R., Gasser C., Bullock A., Ehret S., Woetzel S., Berridge G., Spoo A., Dierks C., Biondi A., Knapp S., Schwaller J. (Basel, München, Oxford, Freiburg/Breisgau, Monza)

FM45

The fusion protein PML-RARA suppresses the master transcription factor PU.1 by targeting the chaperone protein calreticulin.

Vallabhapurapu D., Christen E., Petkovic V., Schardt J., Pabst T., Mueller B.U. (Bern)

FM46

Protein disulfide isomerase (PDI) is upregulated during the unfolded protein response and blocks CEBPA mRNA translation in leukemic cells.

Pabst T., Haefliger S., Eyholzer M., Timchenko N., Mueller B., Pabst T. (Bern, Houston,TX)

FM47

Myeloid differentiation of leukemic cells critically depends on autophagy

Britschgi A., Yousefi S., Simon H.U., Tobler A., Fey M.F., Tschan M.P. (Bern)

FM48

A MOUSE MODEL FOR TESTING THE EFFICACY OF JAK2 INHIBITORS

Kubovcakova L., Hao-Shen H., Looser R., Pianta A., Schaub F., Lundberg P., Skoda R.C. (4031, Basel)

FM49

Disruption of GAS6-MER Pathway Leads to Defects in Physiological Clearance of Expelled Nuclei from Erythroblasts by Bone Marrow Macrophages

Kadi l., Burnier L., Rocco S., Carmeliet P., Lemke G., Earp S., Matsushima G., Schapira M. (Lausanne, Belgium, USA

 

 

 

Communications libres SSH session 2

11h15 – 12h45

Hemostasis, Vascular Biology and Transfusion Medicine

Chairpersons: Behrouz Mansouri, Bern / Anne Angelillo-Scherrer, Lausanne

FM50

Erythrocytes from hyperlipemic donors have a higher rate of hemolysis after storage

Schulzki T., Reinhart W. (Chur)   

FM51

Diagnostic value of platelet flow-cytometric analysis in patients with clinically relevant bleeding diathesis and unrevealing laboratory work-up

Alberio L., Conte T., Pavicic M., Reusser M., Barizzi G., Keller P. (Bern)    

FM52

Vinorelbine and Pegfilgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Multiple Myeloma: A Predictive and Cost Effective Procedure

Bargetzi M., Pabst T., Schoenenberger A., Burger J., Fernandez P., Moosmann P., Mansouri B., Huber A., Baerlocher G., Wernli M., Heizmann M. (Aarau, Bern)    

FM53

Massively Reduced Arachidonic Acid in Red Cell Membranes and in Adipose Tissues with a Diet Rich in Alpha-Linolenic Acid which Diminishes Atherosclerosis in Apolipoprotein E-Deficient Mice

Beer J.H., Matter C., Lohmann , Richter , Leiber , Tanner F., Lüscher T. (Baden, Zürich)    

FM54

The Gain of Function Platelet Polymorphism of GPIb alpha (5T/C) is Overrepresented in Smokers with Symptomatic Carotid Stenosis: An Exploratory Study

Beer J.H., Lugli-Kopp , Brown M., Steffel , Büchi , Spleiss , Förnzler , Dupont , Gaussem , Forestier (Baden, London, Basel, Paris)    

FM55

Klinische Fassetten des hereditären Angioödems (HAE) bei einem Schweizer Patientenkollektiv

Wuillemin W.A., Wuillemin W.A. (Luzern)    

FM56

GENERATION AND PHENOTYPIC ANALYSIS OF PROTEIN S-DEFICIENT MICE

Saller F., Brisset A.C., Azevedo M., Chrast R., Schapira M., Griffin J.H., Angelillo-Scherrer A. (Lausanne, Service and Central Laboratory of Hematology, CHUV, Lausanne, Department of Medical Genetics, UNIL, Lausanne, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, USA)    

FM57

Pharmacokinetics of dalteparin in therapeutic dosage in patients with renal insufficiency

Schmid P., Brodmann D., Odermatt Y., Fischer A.G., Wuillemin W.A. (Luzern)    

FM58

Congenital or acquired ADAMTS13 deficiency or both – that’s the question.

Meyer S.C., Sulzer I., Mäder G., George J.N., Lämmle B., Kremer Hovinga J.A. (Bern, Oklahoma City)

 

 

  Communications libres SSH session 3
14h00 – 16h30

Clinical Hematology

Chairpersons: Jakob Passweg, Genève / Urs Schanz, Zürich

FM59

25 years of stem cell transplantation in Geneva. Impact of immunotherapy using donor derived T-cells. Review and Outlook

Chalandon Y., Roosnek E., Helg C., Kindler V., Huguet S., Mohty B., Mach-Pascual S., Ansari M., Tiercy J.M., Miralbell R., Chapuis B., Passweg J. (Genève)

FM60

Late Altered Organ Function in Long Term Survivors after Allogeneic HSCT: A Paired Comparison with their Identical Sibling Donor.

Rovo A., Daikeler T., Halter J., Heim D., Studt J.D., lMedinger M., Arber C., Stern M., Tsakiris D., Tyndall A., Gratwohl A., Tichelli A. (Basel)

FM61

“Late altered immunity” a distinct entity in long term survivors after allogeneic HSCT?

Rovo A., Daikeler T., Halter J., Heijnen I., Heim D., Arber C., Tyndall A., Gratwohl A., Tichelli A. (Basel)

FM62

Severe immune hemolysis and pure red cell aplasia after haploidentical nonmyeloablative allogeneic stem cell transplantation

Nair G., Mischo A., Stussi G., Schanz U. (Zürich)

FM63

Rituximab for chronic Graft-versus-host disease

Nair G., Schanz U., Stussi G. (Zürich)

FM64

THE ABUNDANT CD56bright NK-CELL POPULATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) ARE CYTOKINE ACTIVATED- RATHER THAN IMMATURE NATURAL KILLER CELLS

Vukicevic M., Chalandon Y., Helg C., Matthes T., Dantin C., Huard B., Passweg J., Roosnek E. (Genève)

FM65

Prospective registration and follow up of donors of allogeneic hematopoietic stem cells (HSC) in a common protocol for related and unrelated donors: experience of the first 18 month

Halter J., Nicoloso-de Faveri G., Buhrfeind E., Baldomero H., Chalandon Y., Huguet S., Stüssi G., Güngör T., Seger , Passweg J., Schanz U., Gratwohl A. (Basel, Bern, Genève, Zürich)

FM66

First Results of the GRAAPH-2005 Study in younger Adult Patients with De Novo Philadelphia Positive Acute Lymphoblastic Leukemia

Chalandon Y., Thomas X., Hayette S., Cayuela J.M., Abbal C., Escoffre-Barbe M., Maury S., Lepretre S., Witz F., Malfuson J.V., Leguay T., Buzyn A., Dombret H. (Genève, GRAALL group Lyon France, GRAAL group Lyon France, Hôptital Saint Louis, Paris, France, CHUV, Lausanne, Hôpital Ponchaillou, Rennes, GRAAL group, Lyon, France, Hôpitaux de Brabois, Nancy, France, CHU de Bordeaux, France)

FM67

Investigating acute leukemias with gene expression arrays in a routine setting: a pilot study from the Geneva University Hospital

Matthes T., Rossier M., Rebsamen M., Chiappe A., Diemand A., Schindela S., Johnson A., Liu W.m., Wieczorek L., Haferlach T., Kohlmann A. (Genève, Munich, Pleasanton)

FM68

Acute lymphoblastic leukemia in childhood: proliferation at different stages of immunophenotypic maturation

Hirt A., Schmid A.M., Leibundgut K. (Bern)

FM69

Platelet transfusion threshold for central venous catheter insertion in patients with hematological malignancies

Zeidler K., Arn K., Senn O., Schanz U., Stüssi G. (Münsterlingen, Zürich)

FM70

Divisional Heterogeneity in Long-Term Hematopoietic Stem Cells

Takizawa H., Boddupalli S., Manz M. (Bellinzona)

FM71

Increased somatic mutation rate in hematopoietic cells from MPD patients is detectable prior to the acquisition of the JAK2-V617F mutation

Lundberg P., Skoda R., Rischewski J., Tichelli A. (Basel)

FM72

The first case of IRIDA in Switzerland: characterisation of two novel mutations and successful treatment by continuous i.v. iron infusion.

Tchou I., Diepold M., Villard J., Swinkels D., Neerman-Arbez M., Beris P. (Dep. of Internal Medicine, HUG, Geneva, Pediatric Clinic, Bern Univ. Hospital, Radboud Universiteit Nijmegen, NL, Medical Genetics, CMU-Geneva)